Menu
Search
|

Menu

Close
X

Advaxis Inc ADXS.OQ (NASDAQ Stock Exchange Global Select Market)

1.80 USD
-- (--)
As of Feb 22
chart
Previous Close 1.80
Open --
Volume --
3m Avg Volume 206,817
Today’s High --
Today’s Low --
52 Week High 10.05
52 Week Low 1.80
Shares Outstanding (mil) 41.54
Market Capitalization (mil) 74.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
12
FY16
4
FY15
0
EPS (USD)
FY17
-2.302
FY16
-2.074
FY15
-1.667
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
6.22
8.08
Price to Book (MRQ)
vs sector
1.37
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-87.28
13.67
Return on Equity (TTM)
vs sector
-107.67
15.40

EXECUTIVE LEADERSHIP

David Sidransky
Independent chairman of the Board, Since 2015
Salary: $97,750.00
Bonus: $204,000.00
Anthony Lombardo
Interim Chief Executive Officer, Since 2017
Salary: $177,500.00
Bonus: $184,000.00
James Patton
Non-Executive Independent Vice Chairman of the Board, Since 2015
Salary: --
Bonus: --
Sara Bonstein
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $338,931.00
Bonus: $671,000.00
Robert Petit
Executive Vice President, Chief Scientific Officer, Since 2013
Salary: $337,689.00
Bonus: $930,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

305 College Rd E
PRINCETON   NJ   08540-6608

Phone: +1732.5451590

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

SPONSORED STORIES